pacritinib
cti biopharma
['mpnsm', '#mpn', 'pacritinib', 'hovon-134']
congress #eha2023 | ruben van dijck, presents a final analysis of the phase ii hovon-134 trial of selective jak2/irak1/acvr1 inhibitor pacritinib. the treatment appears to be a safe and effective pre-transplant strategy for patients with mf. #mpnsm #medicalcongress 
Lifting levels of knowledge in myeloproliferative neoplasms (MPN). A global online platform providing latest treatment options and medical information #mpnsm